Eupraxia Pharmaceuticals Inc.
EPRX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001581178
No open-market purchases or sales by Eupraxia Pharmaceuticals Inc. insiders were filed in the last 90 days; 67 institutions reported holding it in 13F filings for Q2 2026, worth $163.6M in total; no superinvestor holds it.
Q3 2025 vs. Q2 2025
How the institutions holding Eupraxia Pharmaceuticals Inc. changed between Q2 2025 and Q3 2025.
All holders in Q3 2025All holders in Q2 2025
| Measure | Q2 2025 | Q3 2025 | Change |
|---|---|---|---|
| Holders | 14 | 27 | +13 |
| Shares | 1.97M | 12.8M | +10.8M (+550.4%) |
| Value | $10.9M | $75.3M | +$64.4M (+591.4%) |
New holders (15)
Institutions that held Eupraxia Pharmaceuticals Inc. at the end of Q3 2025 but not at the end of Q2 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Beutel, Goodman & Co Ltd. | 4,058,899 | $23.9M | 0.14% |
| Balyasny Asset Management LLC | 1,350,000 | $7.96M | 0.02% |
| Vivo Capital, LLC | 1,350,000 | $7.96M | 0.64% |
| Great Point Partners LLC | 1,200,000 | $7.08M | 2.96% |
| Ally Bridge Group (NY) LLC | 915,000 | $5.40M | 4.52% |
| Logos Global Management LP | 900,000 | $5.31M | 0.52% |
| Velan Capital Investment Management LP | 352,000 | $2.08M | 1.95% |
| Affinity Asset Advisors, LLC | 300,000 | $1.77M | 0.16% |
| Alyeska Investment Group, L.P. | 250,000 | $1.48M | 0.00% |
| Guardian Partners Inc. | 24,130 | $147.4K | 0.01% |
| Acadian Asset Management LLC | 21,400 | $125.0K | 0.00% |
| Integrated Wealth Concepts LLC | 12,000 | $70.8K | 0.00% |
| TCI Wealth Advisors, Inc. | 11,000 | $64.9K | 0.00% |
| Federation des caisses Desjardins du Quebec | 9,091 | $51.6K | 0.00% |
| Tower Research Capital LLC (TRC) | 9 | $53 | 0.00% |
Sold out (2)
Institutions that held Eupraxia Pharmaceuticals Inc. at the end of Q2 2025 and filed for Q3 2025 without it.
| Institution | Shares, Q2 2025 | Value, Q2 2025 |
|---|---|---|
| Citadel Advisors LLC | 18,236 | $108.0K |
| Quadrature Capital Ltd | 10,700 | $61.4K |